Fidelity International

Capital Markets Gateway Inc. is a financial technology firm based in Chicago, Illinois, with additional locations in New York and Seattle. Founded in 2015, the company focuses on modernizing equity capital markets by providing a platform that delivers real-time information and analytics to investors, underwriters, and issuers. This platform enables users to monitor capital raising activities, conduct due diligence, and make informed investment decisions while facilitating collaboration among participants. Since its launch in 2017, Capital Markets Gateway has garnered the trust of over 100 buy-side firms, managing a combined $20 trillion in assets under management, along with support from 10 investment banks. The platform emphasizes transparency and workflow efficiencies, serving as a digital system of record for firm-wide deal activity.

Celestial AI is a prominent artificial intelligence company that provides an advanced platform for users to efficiently create images, text, and presentations. Utilizing computer vision algorithms and natural language processing, the platform produces high-quality visual and textual content. Its intuitive design and innovative features simplify the creation process, while intelligent data integration and a commitment to security ensure reliable results.

Beta Technologies specializes in the design and development of electric aircraft, including advanced flight control and electric propulsion systems, with a strong emphasis on clean aviation technology. The company aims to establish a new paradigm for transporting goods and people through its self-sufficient electric vertical takeoff and landing (eVTOL) aircraft ecosystem. This ecosystem is designed to meet human mobility needs while adhering to environmental principles. Additionally, Beta Technologies is working on a comprehensive electric transportation system that features net-zero, all-electric aircraft and a multimodal charging infrastructure to support various electric vehicles. The company also offers training programs for pilots and maintenance personnel, catering to clients in the cargo, passenger, and emergency response sectors, and enabling them to implement more efficient, cleaner, and faster transportation solutions.

Waymo is a self-driving technology company focused on enhancing mobility by creating safe and efficient transportation solutions. Established from advancements in Google's research since 2009, Waymo aims to improve the movement of people and goods through its innovative software and sensor technology. In 2015, the company marked a significant milestone by conducting the world's first fully autonomous trip on public roads in a vehicle devoid of traditional driving controls. Waymo continually refines its technology through extensive simulation testing, accumulating over one billion miles of virtual testing annually, while its autonomous vehicles have logged more than two million miles on public roads in four U.S. cities. By employing integrated sensors and artificial intelligence, Waymo's technology is designed to detect various obstacles such as pedestrians, cyclists, and road conditions, ensuring a safe and convenient on-demand travel experience for users.

Frore Systems is a technology company based in San Jose, California, with additional offices in Taiwan and South Korea. It specializes in the development of advanced thermal solutions for consumer devices, focusing on active cooling technologies. The company's flagship products, AirJet® Mini and AirJet® Pro, utilize piezoelectric MEMS technology to provide efficient and silent heat dissipation. These cooling chips significantly enhance device performance and offer a solid-state alternative to traditional fans, setting new benchmarks for the computing industry. Frore Systems aims to improve the overall user experience by enabling device manufacturers to implement high-performance cooling solutions in their products.

CoreWeave is a company that specializes in developing a cloud infrastructure platform aimed at providing powerful computing resources for artificial intelligence/machine learning (AI/ML) projects and other initiatives. Their platform features a specialized GPU cloud system designed to accelerate workflows by matching the complexity of models, allowing clients to scale efficiently and adapt to rapidly changing compute requirements. This enables clients to design and innovate with various types of compute resources tailored to their specific needs.

SiMa.ai is a company based in San Jose, California, focused on designing and developing a machine learning platform that provides a single-chip solution for embedded systems. The company specializes in machine learning system-on-chip (MLSoC) technology, which allows for high-performance machine learning inference at low power in edge applications. SiMa.ai's platform enables seamless deployment and scaling of machine learning solutions, addressing various computer vision challenges with significantly improved performance and energy efficiency. The hardware-to-software stack of SiMa.ai is adaptable to multiple frameworks and models, enhancing the capabilities of applications in areas such as computer vision and generative AI. Founded in 2018, SiMa.ai aims to facilitate the integration of advanced machine learning technology into embedded systems while ensuring safe and secure operations.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Lightmatter, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in developing AI hardware using integrated optical technology. The company's core product is a silicon chip that processes data using light signals instead of electrical signals, aiming to significantly accelerate AI computations. Lightmatter targets sectors such as artificial intelligence, cloud computing, and telecommunications, with a focus on improving efficiency and reducing power consumption in critical operations like image recognition and natural language processing.

Vention Inc. is a digital manufacturing platform based in Montreal, Canada, that simplifies the design and ordering of custom machines. Established in 2016, the company provides a cloud-based 3D Machine Builder, which allows engineers and manufacturing professionals to design, order, and assemble custom factory equipment quickly. This platform features an extensive library of modular parts, including structural, motion, and control components, facilitating the creation of automated equipment, robot cells, tooling, and conveyors. Additionally, Vention's offerings include MachineMotion, which aids both automation specialists and novices in automating their designs. By integrating artificial intelligence to enhance the design process, Vention enables users to program, simulate, and commission automated equipment within a single digital environment, making industrial automation more accessible.

Coin Metrics Inc. is a provider of blockchain and cryptocurrency data analytics, based in Cambridge, Massachusetts. Founded in 2017, the company specializes in delivering market and network data, analytics, and research to various industries and institutions involved in crypto-assets. Its offerings include the CM Network Data Pro, which provides comprehensive historical data on top cryptocurrency assets, and the CM Market Data Feed, which standardizes trade, candle, and order book data from multiple exchanges. Additionally, Coin Metrics offers CM Reference Rates, which present fixed asset pricing in U.S. dollars. By focusing on transparency and actionable data, Coin Metrics aims to empower individuals and organizations to make informed financial decisions related to cryptocurrencies.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Menlo Micro, Inc. specializes in the design and development of electronic switches, particularly through its innovative Ideal Switch technology. This electromechanical switch is capable of handling both AC/DC and RF signals, making it suitable for a range of applications including high-power tunable resonators, filters, broadband power amplifier impedance matching, and electronically steerable antennas. The company's products are utilized in various industries, such as battery management, home automation, electronic vehicles, medical instrumentation, and the industrial Internet of Things, as well as in next generation 5G mobile networks. Founded in 2016 and headquartered in Irvine, California, Menlo Micro aims to enhance the efficiency and performance of advanced systems under high-stress conditions.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Astera Labs is a fabless semiconductor company based in Santa Clara, California, established in 2017. The company specializes in designing and supplying semiconductors and connectivity solutions tailored for data-centric systems. Its product range includes system-aware semiconductor integrated circuits, high-speed mixed-signal connectivity products, and various system components like PCIe smart retimers, riser cards, and GPU booster cards. Astera Labs focuses on enhancing PCIe connectivity to address performance bottlenecks in compute-intensive environments, such as server connectivity, distributed machine learning, and high-end gaming graphics. The company collaborates with processor vendors, cloud service providers, and manufacturing partners to deliver critical connectivity performance and facilitate flexibility and customization in their clients' systems. Astera Labs also offers design and testing services, alongside its COSMOS software suite, which enhances observability and predictive analytics in connectivity solutions.

Veterinary Emergency Group specializes in providing emergency and urgent care for pets, operating during nights, weekends, and holidays to address acute medical issues as they arise. The organization is dedicated to delivering timely medical attention to pets and their families in critical situations. With a network of clinics staffed by trained emergency-focused personnel and equipped with advanced diagnostic tools, Veterinary Emergency Group emphasizes a customer-centered approach that ensures rapid response times year-round.

Redwood Materials, Inc. is a Nevada-based company focused on advancing sustainable battery recycling technologies to create a circular supply chain for lithium-ion batteries. Founded by JB Straubel in 2017, Redwood specializes in the recycling and processing of end-of-life batteries and electronics to recover critical materials such as lithium, nickel, cobalt, copper, and various metals. The company currently receives approximately 10 GWh of used batteries annually and aims to scale its production of anode and cathode materials to 100 GWh by 2025, sufficient for manufacturing over one million electric vehicles each year. By providing environmentally sound solutions for recycling and refining, Redwood supports industries including electric vehicles, renewable energy storage, and consumer electronics, thereby contributing to a reduction in the environmental impact of battery production and usage.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

SHINE Technologies, LLC is a medical technology company that specializes in the production and supply of medical tracers and cancer treatment elements. It primarily manufactures and distributes molybdenum-99 (moly-99), a key isotope used in the diagnosis and staging of various diseases, including cancer and heart disease. Additionally, SHINE offers iodine-131 and iodine-125 for treating thyroid cancer and other abnormal thyroid conditions, as well as for diagnosing liver function, kidney blood flow, and urinary tract obstruction. The company also provides xenon-133 for evaluating lung function and blood flow, particularly in the brain. SHINE's products are used extensively in the United States and internationally. Founded in 2010, the company is headquartered in Janesville, Wisconsin, with an additional office in Alkmaar, the Netherlands.

Tenstorrent Inc. is a Canadian company that develops and manufactures application-specific integrated circuits (ASIC) focused on artificial intelligence and machine learning. Founded in 2016 and headquartered in Toronto, with an additional office in Austin, Texas, Tenstorrent specializes in providing scalable and efficient hardware solutions for various applications, ranging from battery-powered Internet of Things (IoT) devices to large cloud servers. The company’s architecture supports deep learning and enables adaptability in algorithms, catering to developers and researchers in the technology sector. By offering advanced AI hardware and software, Tenstorrent aims to enhance computational performance and facilitate the growth of machine learning technologies.

ASAPP, Inc. develops AI-native products designed to address large-scale inefficiencies in various industries. Its core offering, the ASAPP Customer Experience Performance (CXP) platform, enhances the capabilities of customer care and sales agents by providing real-time guidance on effective communication and actions during customer interactions, whether on phone calls or digital messages. The platform's machine learning models continuously learn and adapt from each customer engagement, effectively transforming every agent into a top performer without the need for extensive training or manual programming. ASAPP’s solutions are utilized by major companies in sectors such as telecom, financial services, and travel. Founded in 2014 and headquartered in New York, ASAPP also has locations in San Francisco, Mountain View, London, Buenos Aires, Ithaca, and Raleigh.

Moneytree is a fintech data platform focused on enhancing financial connectivity for individuals and institutions, aiming to promote personal wealth growth. Established in 2013, the company launched its first product, a personal finance app for iOS, which received multiple accolades, including recognition as one of the App Store’s “Best of” apps in Japan shortly after its release. The app has since attracted over 1,300,000 users across iOS, Android, and web platforms. Moneytree's proprietary data aggregation platform, Moneytree LINK, serves nearly twenty enterprise clients, including Japan's largest accounting software vendors, and features integrations with notable financial institutions such as Mizuho Bank and SMBC. This platform enables users to connect their bank accounts and credit cards, providing real-time notifications about significant transactions, low balances, and upcoming bills, thereby facilitating better financial management.

Wasabi Technologies, Inc. is a Boston-based company that offers a cloud storage platform tailored for hybrid and multi-cloud media workflows. Founded in 2016, Wasabi provides hot storage solutions that utilize an Amazon S3 compatible API, enabling organizations to store and access data quickly, with average time-to-first-byte speeds under 15 milliseconds. The company's platform is designed to be simple and affordable, allowing customers to access unlimited data without complex pricing tiers or unpredictable egress fees. Wasabi's services cater to various industries, including media and entertainment, education, scientific research, law enforcement, healthcare, and energy. The company has gained recognition for its rapid growth and innovative approach to cloud storage, serving tens of thousands of customers worldwide.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Emalex Biosciences is a biotechnology startup focused on developing innovative treatments for central nervous system (CNS) disorders and rare neurological conditions. Founded in 2018 by Jeff Aronin, the company is advancing its lead candidate, Ecopipam, which has been explored as a potential therapy for various CNS disorders, including pediatric Tourette Syndrome and fluency disorders. Emalex aims to address the needs of patients with rare diseases that currently have limited or no treatment options, collaborating with patient advocacy organizations and medical researchers to facilitate the development of effective biopharmaceutical therapies.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.

Pony.ai, Inc. is a technology company specializing in autonomous driving solutions and artificial intelligence software for automated vehicle manufacturing. Founded in 2016 and headquartered in Fremont, California, with additional offices in San Francisco and China, Pony.ai develops systems that utilize machine learning to navigate vehicles across diverse driving conditions. The company's technology focuses on accurately perceiving the vehicle's environment and predicting driver actions to enhance safety and functionality. In addition to its core development efforts, Pony.ai also operates a public-facing Robotaxi service, showcasing its advancements in autonomous mobility. Through collaborations with automotive manufacturers, Pony.ai aims to integrate its innovative technology into commercial vehicles, significantly contributing to the evolution of transportation.

Rad Power Bikes LLC, based in Seattle, Washington, is a leading manufacturer and retailer of electric bicycles in North America. Founded in 2015, the company specializes in designing feature-rich e-bikes suitable for both on and off-road use, catering to a diverse range of consumer needs. In addition to its electric bikes, Rad Power Bikes offers a variety of accessories such as bags, fenders, racks, and safety products, as well as replacement parts like batteries and tires. The company operates on a direct-to-consumer model, selling its products primarily through online platforms, which allows it to provide affordable and accessible transportation solutions. With a rapidly expanding workforce exceeding 700 employees, Rad Power Bikes is committed to revolutionizing electric mobility and promoting energy-efficient transportation options.

Vera Therapeutics, a biotechnology company based in South San Francisco, California, specializes in developing innovative biologic therapeutics aimed at treating serious immunological diseases and genetic disorders. Founded in 2016 and renamed in March 2020, the company's research focuses on transformative treatments that can significantly improve patient outcomes. One of its key product candidates is atacicept, a fusion protein designed for self-administration via a weekly subcutaneous injection. Atacicept works by inhibiting both B lymphocyte stimulator and a proliferation-inducing ligand, which are involved in the production of autoantibodies that contribute to various autoimmune diseases. Additionally, Vera Therapeutics is exploring gene-editing technologies that hold the potential to address conditions such as sickle cell disease and cystic fibrosis.

dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.

Nuro, Inc. is a technology company based in Mountain View, California, that specializes in the development of self-driving vehicles specifically designed for local goods transportation. Incorporated in 2016, Nuro aims to transform local commerce through its fleet of fully autonomous, electric vehicles that facilitate the delivery of a wide range of products, including food and pharmaceuticals. By enabling retailers to efficiently and safely deliver goods to customers, Nuro enhances the convenience of local commerce and meets the growing demand for autonomous delivery solutions.

Pony.ai, Inc. is a technology company specializing in autonomous driving solutions and artificial intelligence software for automated vehicle manufacturing. Founded in 2016 and headquartered in Fremont, California, with additional offices in San Francisco and China, Pony.ai develops systems that utilize machine learning to navigate vehicles across diverse driving conditions. The company's technology focuses on accurately perceiving the vehicle's environment and predicting driver actions to enhance safety and functionality. In addition to its core development efforts, Pony.ai also operates a public-facing Robotaxi service, showcasing its advancements in autonomous mobility. Through collaborations with automotive manufacturers, Pony.ai aims to integrate its innovative technology into commercial vehicles, significantly contributing to the evolution of transportation.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

SHINE Technologies, LLC is a medical technology company that specializes in the production and supply of medical tracers and cancer treatment elements. It primarily manufactures and distributes molybdenum-99 (moly-99), a key isotope used in the diagnosis and staging of various diseases, including cancer and heart disease. Additionally, SHINE offers iodine-131 and iodine-125 for treating thyroid cancer and other abnormal thyroid conditions, as well as for diagnosing liver function, kidney blood flow, and urinary tract obstruction. The company also provides xenon-133 for evaluating lung function and blood flow, particularly in the brain. SHINE's products are used extensively in the United States and internationally. Founded in 2010, the company is headquartered in Janesville, Wisconsin, with an additional office in Alkmaar, the Netherlands.

Prelude Therapeutics is a clinical-stage precision oncology company based in Wilmington, Delaware, founded in 2016 by Krishna Vaddi. The company is focused on discovering and developing novel small-molecule therapies that target key mechanisms driving cancer cell growth, survival, and resistance, addressing significant unmet medical needs in oncology. Prelude's pipeline includes four clinical candidates: PRT1419, a selective inhibitor of MCL1; PRT2527, a selective CDK9 inhibitor; PRT3645, a next-generation CDK4/6 inhibitor; and PRT3789, a first-in-class SMARCA2/BRM protein degrader. Through these innovative therapies, Prelude aims to provide healthcare providers with potential treatment options to improve outcomes for patients battling cancer.

Conformal Medical, Inc. is a medical device company focused on developing innovative solutions to prevent stroke in patients with atrial fibrillation, particularly those with non-valvular atrial fibrillation. Founded in 2016 and based in Nashua, New Hampshire, the company offers CLAAS Technology, which is designed for sealing the left atrial appendage (LAA). This proprietary technology aims to enhance the effectiveness of left atrial appendage closure, addressing a critical need in the management of atrial fibrillation.

Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016, that specializes in the development of innovative therapies for cancer treatment. The company's portfolio includes ATG-010 (selinexor), targeting hematologic malignancies such as multiple myeloma, and ATG-008 (onatasertib), an mTOR kinase inhibitor aimed at treating advanced solid tumors and hematological malignancies. Antengene's pipeline features several investigational products, including ATG-016 (eltanexor), ATG-527 (verdinexor), and ATG-019, along with pre-clinical candidates like ATG-101, a bi-specific antibody, and ATG-012, a KRAS G12C inhibitor. The company is committed to addressing unmet medical needs in Asia through its focus on the discovery, development, and commercialization of first-in-class therapeutics for various types of cancer.

ApplyBoard is a technology company that facilitates the study abroad process for international students by connecting them with recruitment partners and educational institutions through a unified platform. The company simplifies the application journey, assisting students from around the globe in discovering, applying to, and enrolling in universities in North America. Founded eight years ago, ApplyBoard has rapidly expanded, employing over 1,200 team members and establishing a presence in 30 countries, including India, China, and the United States. In 2023, it received recognition from Deloitte as one of Canada’s fastest-growing technology companies for the fifth consecutive year, highlighting its significant impact on the education sector and its commitment to empowering students worldwide. The company's headquarters is located in Kitchener, Ontario, with an additional office in Gurugram, India.

Moneytree is a fintech data platform focused on enhancing financial connectivity for individuals and institutions, aiming to promote personal wealth growth. Established in 2013, the company launched its first product, a personal finance app for iOS, which received multiple accolades, including recognition as one of the App Store’s “Best of” apps in Japan shortly after its release. The app has since attracted over 1,300,000 users across iOS, Android, and web platforms. Moneytree's proprietary data aggregation platform, Moneytree LINK, serves nearly twenty enterprise clients, including Japan's largest accounting software vendors, and features integrations with notable financial institutions such as Mizuho Bank and SMBC. This platform enables users to connect their bank accounts and credit cards, providing real-time notifications about significant transactions, low balances, and upcoming bills, thereby facilitating better financial management.

Alignment Health is a healthcare organization focused on providing tailored care solutions for seniors, primarily through Medicare Advantage plans. By offering a consumer-centric platform, it allows seniors to choose their healthcare coverage and services annually. The company emphasizes a combination of technology and clinical coordination to enhance health outcomes, facilitating care through various channels, including phone, online, and in-person settings. Additionally, Alignment Health supports its partners and patients with risk management and customized services, ensuring a comprehensive approach to healthcare delivery.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Innophys Co., Ltd., founded in 2013 and based in Tokyo, Japan, specializes in wearable robotics technology. The company designs, manufactures, and distributes innovative robotics equipment aimed at various industries. Its flagship product, the Muscle Suit®, utilizes artificial muscle technology to provide physical assistance, reducing strain during tasks such as lifting heavy objects or working in bent positions. The Muscle Suit® is recognized for its high quality and competitive pricing compared to other exoskeletons in the market. Innophys aims to expand its reach into the Asia Pacific, European, and North American markets, enhancing the ability of users to perform tasks independently and improve their quality of life.

Revolution Medicines is a clinical-stage precision oncology company dedicated to developing novel targeted therapies for cancer treatment. Founded by Martin D. Burke, the company leverages an innovative approach to synthesize complex natural products into optimized drug candidates. This method involves rapidly assembling simple chemical building blocks into refined structures with significant therapeutic potential. Revolution Medicines focuses on inhibiting elusive targets within key growth and survival pathways, particularly RAS and mTOR signaling pathways. The company's portfolio includes therapies like RMC-4630, a SHP2 inhibitor, as well as programs targeting SOS1 and 4EBP1/mTORC1.

Allbirds, founded in 2015 and based in San Francisco, is an apparel and fashion company specializing in eco-friendly footwear. It manufactures and sells a variety of shoe styles for men, women, and children, including wool runners, tree runners, and loungers, using premium natural materials. The company's mission is to create sustainable footwear that combines comfort, good design, and environmental responsibility. Allbirds operates through its own stores, retail partners, and an online platform, with a significant portion of its revenue coming from the United States market.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Kaleido Biosciences is a clinical-stage healthcare company that focuses on harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the efficient discovery and development of Microbiome Metabolic Therapies (MMTs). These therapies aim to modify the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates targeting various diseases and conditions that address significant unmet patient needs.

Cibus is a biotechnology company specializing in precision gene editing for agriculture, aimed at making farming more sustainable and profitable. The company has developed patented breeding technologies that facilitate precise and predictable modifications in plants without the integration of foreign genetic material. Its core innovation, the Rapid Trait Development System, combines crop-specific cell biology platforms with advanced gene editing techniques. Cibus focuses on creating plant traits that address specific agricultural challenges, including those related to productivity, disease resistance, insect control, weed management, nutrient use, and climate adaptability. Through these efforts, Cibus seeks to enhance the efficiency and sustainability of agricultural practices.

SenseTime Group Limited is an artificial intelligence company specializing in computer vision and deep learning technologies. Founded in 2014 and headquartered in Beijing, China, the company develops a wide range of AI solutions, including face and body analysis, image and video recognition, autonomous driving technologies, and medical image analysis. SenseTime's proprietary AI infrastructure, SenseCore, supports scalable and efficient AI software platforms tailored for various applications across sectors such as smart cities, intelligent transportation, healthcare, and finance. The company is also active in advancing industry standards related to data security and ethical AI practices, having contributed to numerous national and international guidelines. With a presence in multiple countries, including Japan, Singapore, and several locations in China, SenseTime aims to drive innovation and foster sustainable productivity through its AI technologies.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

Atom Tickets, LLC operates a mobile application available on Android and iOS that simplifies the process of purchasing movie tickets and concessions. Founded in 2012 and based in Santa Monica, California, the app allows users to find and buy tickets while also providing features to order food in advance. It enhances the moviegoing experience by offering information such as reviews and trailers, and enabling users to share listings with friends and coordinate group outings. Users can engage with their social networks to poll friends on movie choices, book group seating while handling separate payments, and eliminate the need for physical tickets. Atom Tickets aims to streamline the entire movie experience, keeping all planning and transactions organized in one platform.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatments. Founded in 2014 and based in South San Francisco, the company’s lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which is associated with resistance to various cancer therapies in solid tumors. Its second candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, targeting a critical component of the adenosine pathway linked to resistance against chemotherapy and immunotherapy. In addition to these products, ORIC is advancing multiple precision medicines aimed at addressing other mechanisms of cancer resistance. The company’s founders, Charles Sawyers and Scott Lowe, have extensive experience in identifying novel cancer targets that have led to innovative therapies.

Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. The company has a diverse pipeline of clinical-stage product candidates, including Rilonacept, which is undergoing Phase III trials for recurrent pericarditis; Mavrilimumab, a monoclonal antibody in Phase II trials for giant cell arteritis; and KPL-716, currently in Phase 2a trials for prurigo nodularis and Phase 1a trials for atopic dermatitis. Kiniksa also has preclinical candidates, such as KPL-404, which targets the CD40/CD40L interaction in immune responses. Additionally, the company is collaborating with Kite Pharma to explore the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Founded in 2015 and headquartered in Hamilton, Bermuda, Kiniksa Pharmaceuticals aims to address multiple autoimmune and autoinflammatory conditions through its innovative approaches.

Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Wheels Up is a membership-based private aviation company that specializes in on-demand flight services in the United States. By leveraging data and technology, it connects consumers with safety-vetted private aircraft, offering both programmatic and charter options. The company aims to reduce the upfront costs associated with private flying while providing flexibility, service, and safety to its members. Through its mobile app, users can easily book flights, manage accounts, and access ride-share opportunities. Additionally, members participate in the Wheels Down program, which enhances their travel experiences. Wheels Up operates a diverse fleet, utilizing owned, leased, and chartered aircraft to provide a wide range of global travel alternatives.

Reddit, established in 2005, operates as a social news aggregation, web content rating, and discussion website. It facilitates users to submit links, create content, and engage in discussions on a wide array of topics, from gaming and sports to business and cryptocurrency.

Spring is a retail company that offers a diverse selection of products, including apparel and home and garden items. It operates as a shopping application designed for iOS devices, allowing users to follow their favorite brands and purchase new arrivals, exclusives, and unique products. Originally founded as Jello Labs, the company rebranded to Spring in July 2014. The founders of Spring are David Tisch, Alan Tisch, and Octavian Costache, and the company is based in New York.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

10x Genomics is a life science technology company based in Pleasanton, California, that specializes in developing instruments, consumables, and software for the analysis of biological systems. Founded in 2012, the company offers a range of products, including Chromium instruments, microfluidic chips, slides, reagents, and various consumable products. Its innovative single cell solutions enable researchers to assess gene expression, immune profiling, epigenetics, and cellular heterogeneity at an individual cell level. The Visium spatial gene expression solution allows for the analysis of gene expression patterns across tissue samples, providing valuable insights into biological processes. 10x Genomics serves a diverse client base, including academic institutions, government organizations, and biopharmaceutical companies across multiple regions, including North America, Europe, and Asia. The company generates the majority of its revenue from consumables, underscoring its focus on providing essential tools for genomic research.

Magic Leap is an American startup specializing in Augmented Reality (AR) technology. The company develops proprietary wearable hardware that merges digital imagery with the real world, creating immersive AR experiences indistinguishable from reality. Their innovative Dynamic Digitized Lightfield Signal generates computer-generated 3D images that harmonize with human senses, enabling users to interact with digital devices in a visually cinematic manner. Magic Leap aims to redefine how users access screens and visualize data by combining inherent visual ability with mobile computing technology.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Allena Pharmaceuticals is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, that specializes in developing and commercializing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. The company's primary focus is on conditions that involve the excessive accumulation of metabolites such as oxalate and urate, which can lead to complications like kidney stones and chronic kidney disease. Allena's lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a disorder linked to significantly high urinary oxalate levels. Additionally, the company is developing ALLN-346, a novel enzyme designed to address hyperuricemia in patients with moderate to severe chronic kidney diseases. Allena Pharmaceuticals aims to provide innovative treatments that address unmet medical needs in these patient populations.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

Handy, founded in 2012, is an online platform that provides a reliable and convenient way for customers to book household services, including home cleaning, plumbing, and home renovations. Operating in the United States, Canada, and the United Kingdom, Handy allows users to schedule appointments with pre-approved, experienced, and background-checked professionals in just a few minutes. The platform has facilitated millions of bookings, serving over 500,000 customers and activating over 50,000 independent service providers. Handy aims to connect homeowners with a wide range of services, from routine cleanings to more complex tasks like major renovations. Customers can easily access these services through the Handy app or website, ensuring that their home maintenance needs are met efficiently and at a high standard. With a focus on customer satisfaction, Handy offers a guarantee to address any issues that may arise, reinforcing its commitment to providing a dependable and stress-free experience for homeowners.

Bracket Computing Inc. specializes in workload isolation software that enables enterprises to securely manage workloads in hybrid cloud environments. Founded in 2011 and based in Mountain View, California, the company provides advanced IT security measures, including crypto-enforced micro-segmentation, which ensures continuous encryption of data both at rest and in motion, utilizing customer-controlled keys. Its platform also features data and runtime integrity monitoring, along with auditability and forensics capabilities that capture critical information at the time of a security breach. By consolidating security controls, Bracket Computing aims to protect enterprises from malware, insider threats, and human errors, all while maintaining the agility and speed of self-service cloud operations.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Made.com Design Limited specializes in designing, manufacturing, and distributing high-end furniture, making luxury home design accessible to consumers. Founded in 2009 and based in London, the company connects customers directly with designers, eliminating middlemen to offer high-quality, made-to-order products at competitive prices. Made.com features a diverse range of furniture, including sofas, chairs, tables, lighting, storage solutions, and bedding, catering to various styles and needs. By selling exclusively online and avoiding showrooms and warehouses, the company minimizes waste and surplus stock, producing items in response to grouped customer orders every seven days. This approach enables Made.com to provide furniture typically priced 70-85% lower than traditional retailers. The brand collaborates with renowned designers and skilled craftsmen, ensuring quality while maintaining affordability. With a growing customer base, Made.com continues to transform the furniture market by offering stylish, well-crafted pieces that enhance home environments.

Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, founded in 2009. The company focuses on developing small molecule drugs aimed at treating chronic pain and various neurogenic disorders by targeting P2X3 receptors in nerve fibers. Its lead compound, AF-219, has completed two Phase 1 clinical studies and is designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy, as well as respiratory and urological issues.

PAX Labs, Inc. is a manufacturer of premium vaporizers and accessories designed for loose-leaf and concentrates. The company's product lineup includes the PAX 3, PAX 2, and PAX Era, along with various accessories and a mobile application that enhances user experience. PAX Labs aims to simplify cannabis consumption by providing products that emphasize quality, transparency, and predictability. The company distributes its products through a network of retailers and distributors across the United States and internationally, as well as through its online platform. Founded in 2004 and headquartered in San Francisco, California, PAX Labs has established itself as an industry leader through innovation and thoughtful product design.

JUUL is an electronics company based in San Francisco, California, that focuses on providing alternatives for adult smokers through its nicotine vaporizer products. The company aims to eliminate combustible cigarettes by offering a satisfying and less harmful option for the estimated one billion smokers worldwide. JUUL's product line includes e-cigarettes and a variety of free-base nicotine flavors made from natural oils and extracts, designed to help users transition from traditional tobacco smoking. Research conducted by JUUL indicates that hundreds of thousands of smokers have successfully switched to their products, with the company committed to facilitating this transition for millions more in the future.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

Blue Bottle Coffee is a coffee roaster and retailer based in Oakland, California, specializing in delivering high-quality coffee subscriptions directly to customers' doorsteps across the nation. The company operates a network of cafes in key locations, including the Bay Area, Los Angeles, New York, and Tokyo, offering a diverse range of products such as instant coffee, seasonal collections, brew tools, and drinkware. Blue Bottle Coffee emphasizes organic practices, ensuring that its offerings align with health-conscious consumption. With a dedicated team, the company is committed to providing exceptional coffee experiences, whether in their cafes or at home.

Axcella Health Inc., established in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions targeting various biological pathways. The company's pipeline includes AXA1665 for hepatic encephalopathy, AXA1125 and AXA1957 for non-alcoholic steatohepatitis, AXA2678 for muscle atrophy, and AXA4010 for multiple biological pathways.

Hootsuite is a social media management platform that assists businesses in engaging with their customers across various social media channels. The platform provides a comprehensive suite of tools designed to simplify marketing efforts, enhance sales, and improve customer service. Users can create, schedule, publish, and manage content and advertising campaigns from a single, secure web-based dashboard. Hootsuite's features enable organizations to manage all their social media profiles efficiently, discover effective content, and analyze trends through relevant data insights. This functionality helps businesses optimize their social media strategies and connect more effectively with their audiences.

Manthan is a leading cloud analytics company for consumer facing businesses. We excel in the application of decision sciences, advanced math and artificial intelligence and have a restless ability to invent and bring ideas to life. Manthan’s analytics solutions are powered by AI, cloud and prescriptive capabilities. They are unique in their ability to use machine intelligence to process every decision context and respond automatically with actions and recommendations to manage every aspect of a consumer business, whether its marketing, merchandising, channel/store, demand or supply. Manthan’s inventions aim to bring a new paradigm of context-aware, automated and algorithmic business decisions and actions, executed at scale.

Kobo is an e-reading platform that offers a wide range of digital content through its eBook store, with nearly 4 million titles available in 68 languages. Users can access this content on various devices using e-reader apps for Apple, BlackBerry, Android, and Windows platforms. Kobo also provides a seamless reading experience by allowing bookmarks to synchronize across devices. With a global reach spanning 190 countries and partnerships with 17,600 locations worldwide, Kobo has established itself as a leading digital reading provider since its founding in 2009, headquartered in Toronto, Ontario.

Zynga Inc., established in 2007, is a leading global developer, publisher, and operator of social games. The company's portfolio spans over 6 billion downloads across 175 countries, featuring popular franchises like FarmVille, Words With Friends, and Zynga Poker. Zynga's games are played on mobile platforms (iOS, Android) and social networking sites, with revenue generated through game downloads, in-game purchases, and advertising services. The company's headquarters are in San Francisco, California, with additional locations in North America, Europe, and Asia.

BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Exit41's Software as a Service (SaaS) social ordering solutions have processed over twenty million food orders for consumers on behalf of leading restaurant brands across the globe including Qdoba Mexican Grill, la Madeleine, Cara Operations, Americana Group and Lettuce Entertain You Enterprises. Exit41's web and mobile applications enable restaurants to connect with, recognize and reward their customers and build loyal, profitable relationships. Founded in 1999, Exit41 is headquartered in Andover, Massachusetts, and is backed by tier one investors including GrandBanks Capital and Dace Ventures.

Yipes is a data communications services provider. It was acquired in 2007 by Indian telecommunications service provider Reliance Communications. Yipes delivers scalable business-to-business and business-to-Internet IP networking services. Their regional IP network Yipes MAN seamlessly extends your company's LAN to other business locations or to business partner locations. Their Yipes NET Internet service brings the Web to your LAN at breakaway speeds. Yipes NET customers can also take advantage of Yipes' industry-leading security offering Yipes WALL managed firewall service, to safeguard their private information from the dangers of the public Internet. Yipes NAN replaces private line and frame relay services with the simplicity of Ethernet. Yipes WEB offers a full portfolio of Internet management services. Yipes TOUGH enables customers to extend the redundancy on their customer premise to the Yipes Network.

Terabeam is an American company that designs and manufactures free-space optical transceivers for internet access in downtown areas. Terabeam was founded in 1997 and is located in Kirkland, Washington. As of August 29, 2008, the company operates as subsidiary of Renaissance Electronics & Communications LLC.